Statins
Statins - Related Videos
01:20
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
0 Views •
2024
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
15:41
Improved Visualization and Quantitative Analysis of Drug Effects Using Micropatterned Cells
0 Views •
Cited by 14 •
2010
Adhesive micropatterns that normalize cellular architecture can be used to increase sensitivity in the detection of drug effects, improve reproducibility and simplify automated image acquisition and analysis. Such technology will benefit drug/siRNA screening assays, performed on conventional cell culture supports and consequently suffering from excessive cell-to-cell variability.
07:20
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
0 Views •
Cited by 6 •
2011
An efficient protocol for the ex vivo expansion of tumor-reactive T cells from tumor-draining lymph nodes or other secondary lymphoid tissues of tumor-bearing hosts is described. This protocol selectively expands tumor-specific T cells for use in adoptive immunotherapy of breast cancer.
08:13
Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart
0 Views •
Cited by 71 •
2011
This paper details the dissection procedure, instrumental setup, and experimental conditions during optical mapping of transmembrane potential (Vm) and intracellular calcium transient (CaT) in intact isolated Langendorff perfused mouse hearts.
09:24
Multiparametric Optical Mapping of the Langendorff-perfused Rabbit Heart
0 Views •
Cited by 30 •
2011
This article describes the basic procedures for conducting optical mapping experiments in the Langendorff-perfused rabbit heart using the panoramic imaging system, and the dual (voltage and calcium) imaging modality.
FAQs
Competitive inhibition reduces the activity of HMG-CoA reductase, a key enzyme in hepatic cholesterol synthesis. As the liver synthesizes less cholesterol, it increases LDL receptor expression. These receptors remove more LDL from the bloodstream, linking the biochemical action of statins to the reduction in circulating LDL cholesterol and the treatment of dyslipidemia.
Increased hepatic LDL receptor expression strengthens the liver’s ability to clear LDL from the bloodstream. This response is important because the benefit of treatment depends not only on reducing cholesterol synthesis within liver cells, but also on removing existing circulating LDL. The combined effect helps lower exposure to LDL associated with atherosclerotic cardiovascular disease.
The clinical purpose depends on a person’s cardiovascular context. In primary prevention, statins are used for people who have not yet experienced a cardiovascular event but have elevated risk. In secondary prevention, they are used after events such as myocardial infarction or stroke, when reducing further cardiovascular risk becomes an important treatment goal.
Clinicians may consider statins when elevated cardiovascular risk or dyslipidemia makes LDL reduction clinically important. Their use can fit either a primary-prevention strategy for people at elevated risk or a secondary-prevention strategy after myocardial infarction or stroke. The treatment choice reflects the patient’s risk context and the goal of preventing atherosclerotic cardiovascular disease.
Monitoring helps clinicians balance the expected therapeutic benefit with potential adverse effects. It can assess the medication’s effect on cholesterol levels while also supporting attention to tolerability and safety. This ongoing clinical review is relevant because statins are intended to reduce cardiovascular risk, but treatment decisions must account for how the individual responds.
Clinical evaluation can focus on changes in LDL cholesterol, the broader management of dyslipidemia, and the patient’s prevention setting. These outcomes indicate whether treatment is addressing its intended lipid-lowering goal. Over time, the larger objective is to support prevention of atherosclerotic cardiovascular disease, either before an event or after one has occurred.